Journal article
Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin’s lymphoma: results of a pilot study
Abstract
BACKGROUND/OBJECTIVES: Osteopenia is a significant morbidity in children undergoing therapy for acute lymphoblastic leukaemia (ALL) or non-Hodgkin's lymphoma (NHL). We conducted a pilot study to assess the impact of alendronate on whole body bone mineral content (WB-BMC), lumbar spine bone mineral density (LS-BMD), biochemical measures of bone mineral metabolism, as well as gross motor function and health-related quality of life (HRQL) in …
Authors
Wiernikowski J; Barr R; Webber C; Guo C; Wright M; Atkinson S
Journal
Journal of Oncology Pharmacy Practice, Vol. 11, No. 2, pp. 51–56
Publisher
SAGE Publications
Publication Date
June 2005
DOI
10.1191/1078155205jp145oa
ISSN
1078-1552
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Absorptiometry, PhotonAdministration, OralAdolescentAdrenal Cortex HormonesAlendronateBone DensityBone Density Conservation AgentsBone Diseases, MetabolicCalciumCalcium CarbonateChildChild, PreschoolCollagenCollagen Type IFemaleHumansLumbar VertebraeLymphoma, Non-HodgkinMaleOsteocalcinParathyroid HormonePeptidesPilot ProjectsPrecursor Cell Lymphoblastic Leukemia-LymphomaQuality of LifeTime FactorsTreatment OutcomeVitamin D